557 related articles for article (PubMed ID: 19627247)
1. Failure of treatment with first-line lopinavir boosted with ritonavir can be explained by novel resistance pathways with protease mutation 76V.
Nijhuis M; Wensing AM; Bierman WF; de Jong D; Kagan R; Fun A; Jaspers CA; Schurink KA; van Agtmael MA; Boucher CA
J Infect Dis; 2009 Sep; 200(5):698-709. PubMed ID: 19627247
[TBL] [Abstract][Full Text] [Related]
2. Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments.
Garriga C; Pérez-Elías MJ; Delgado R; Ruiz L; Nájera R; Pumarola T; Alonso-Socas Mdel M; García-Bujalance S; Menéndez-Arias L;
J Med Virol; 2007 Nov; 79(11):1617-28. PubMed ID: 17854027
[TBL] [Abstract][Full Text] [Related]
3. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
[TBL] [Abstract][Full Text] [Related]
4. Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.
Luis Jiménez J; Resino S; Martinez-Colom A; Bellón JM; Angeles Muñoz-Fernández M;
J Antimicrob Chemother; 2005 Dec; 56(6):1081-6. PubMed ID: 16195257
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
Kempf DJ; Isaacson JD; King MS; Brun SC; Sylte J; Richards B; Bernstein B; Rode R; Sun E
Antivir Ther; 2002 Sep; 7(3):165-74. PubMed ID: 12487383
[TBL] [Abstract][Full Text] [Related]
6. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
[TBL] [Abstract][Full Text] [Related]
7. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V
J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
[TBL] [Abstract][Full Text] [Related]
8. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Delfraissy JF; Flandre P; Delaugerre C; Ghosn J; Horban A; Girard PM; Norton M; Rouzioux C; Taburet AM; Cohen-Codar I; Van PN; Chauvin JP
AIDS; 2008 Jan; 22(3):385-93. PubMed ID: 18195565
[TBL] [Abstract][Full Text] [Related]
9. Lopinavir/ritonavir resistance in patients infected with HIV-1: two divergent resistance pathways?
Champenois K; Baras A; Choisy P; Ajana F; Melliez H; Bocket L; Yazdanpanah Y
J Med Virol; 2011 Oct; 83(10):1677-81. PubMed ID: 21755502
[TBL] [Abstract][Full Text] [Related]
10. Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens.
Santos JR; Llibre JM; Imaz A; Domingo P; Iribarren JA; Mariño A; Miralles C; Galindo MJ; Ornelas A; Moreno S; Schapiro JM; Clotet B;
J Antimicrob Chemother; 2012 Jun; 67(6):1462-9. PubMed ID: 22431669
[TBL] [Abstract][Full Text] [Related]
11. Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
Malet I; Roquebert B; Dalban C; Wirden M; Amellal B; Agher R; Simon A; Katlama C; Costagliola D; Calvez V; Marcelin AG
J Infect; 2007 Apr; 54(4):367-74. PubMed ID: 16875739
[TBL] [Abstract][Full Text] [Related]
12. Safety and antiviral activity of lopinavir/ritonavir-based therapy in human immunodeficiency virus type 1 (HIV-1) infection.
Kaplan SS; Hicks CB
J Antimicrob Chemother; 2005 Aug; 56(2):273-6. PubMed ID: 15994247
[TBL] [Abstract][Full Text] [Related]
13. Natural polymorphisms in HIV-1 protease: impact on effectiveness of a first-line lopinavir-containing antiretroviral therapy regimen.
Champenois K; Deuffic-Burban S; Cotte L; André P; Choisy P; Ajana F; Bocket L; Yazdanpanah Y
J Med Virol; 2008 Nov; 80(11):1871-9. PubMed ID: 18814256
[TBL] [Abstract][Full Text] [Related]
14. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.
Loutfy MR; Raboud JM; Walmsley SL; Saskin R; Montaner JS; Hogg RS; Thompson CA; Harrigan PR
Antivir Ther; 2004 Aug; 9(4):595-602. PubMed ID: 15456091
[TBL] [Abstract][Full Text] [Related]
16. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
[TBL] [Abstract][Full Text] [Related]
17. Predictive genotypic algorithm for virologic response to lopinavir-ritonavir in protease inhibitor-experienced patients.
King MS; Rode R; Cohen-Codar I; Calvez V; Marcelin AG; Hanna GJ; Kempf DJ
Antimicrob Agents Chemother; 2007 Sep; 51(9):3067-74. PubMed ID: 17576846
[TBL] [Abstract][Full Text] [Related]
18. The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V.
Knops E; Kemper I; Schülter E; Pfister H; Kaiser R; Verheyen J
AIDS; 2010 Mar; 24(5):779-81. PubMed ID: 20139751
[TBL] [Abstract][Full Text] [Related]
19. Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Naeger LK; Struble KA
AIDS; 2006 Apr; 20(6):847-53. PubMed ID: 16549968
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of a fosamprenavir-ritonavir-based versus a lopinavir-ritonavir-based antiretroviral treatment in 82 therapy-naïve patients with HIV-1 infection.
Calza L; Manfredi R; Pocaterra D; Chiodo F
Int J STD AIDS; 2008 Aug; 19(8):541-4. PubMed ID: 18663041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
